Table 1.
Clinical features of metastatic colorectal cancer patients treated with irinotecan-based therapy
| Characteristics | Patients (N = 67) |
|---|---|
| Median age-years (range) | 62 (33–79) |
| Sex | |
| Male | 47 (70%) |
| Female | 20 (30%) |
| Median CEA (range, ng/mL) | 16 (0–2066) |
| Performance status WHO | |
| 0 | 29 (43%) |
| 1 | 35 (52%) |
| 2 | 3 (5%) |
| Site of primary tumor | |
| Colon | 35 (52%) |
| Rectum | 32 (48%) |
| METASTASIS | |
| Liver | 31 (47%) |
| Liver & other | 19 (28%) |
| Other | 15 (22%) |
| N.A. | 2 (3%) |
| KRAS | |
| Wild-type | 35 (52%) |
| Mutated | 26 (39%) |
| N.A. | 6 (9%) |
| BRAF | |
| Wild-type | 60 (90%) |
| Mutated | 7 (10%) |
| Biologic treatment | |
| Bevacizumab | 23 (34%) |
| Cetuximab | 7 (11%) |
| None | 37 (55%) |
| TOPO I expression level | |
| High | 21 (31%) |
| Low | 20 (30%) |
| N.A. | 26 (39%) |
| DEK expression level | |
| High | 21 (31%) |
| Low | 46 (69%) |
N.A.: not available. Other refers to lung, lymph node and/or peritoneal metastasis.